← Leaderboards
Bolin Liu
Lsu Health Sciences Center
$3,068,729
Attributed
$3,068,729
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $416.7K · FY2014–25$500K$375K$250K$125K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,068,729 · 3
By mechanism
R01$2,913,687 · 2
R03$155,042 · 1
Top collaborators
No co-investigators on record.
Most similar at Lsu Health Sciences Center
Same institution · by research overlap
- Jovanny Zabaleta$2,272,829
- Ches'que Phillips$121,106
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularMediatingDrug ResistancePlayTumorMalignant Breast NeoplasmSignal TransductionBioinformaticsOverexpressionNeoplasm MetastasisEpigenetic ProcessMicrornasErbb2 GeneBreast Cancer CellBreast Cancer PatientLightLoss Of FunctionTargeted TreatmentNovel TherapeuticsInsightIn VitroGain Of FunctionIn VivoMetastatic Neoplasm To The Lung
Grant awards (10)
HER3-PHF8 signaling axis in triple-negative breast cancer progression$404,942
R01 · FY2025 · CA · contact PI
HER3-PHF8 signaling axis in triple-negative breast cancer progression$390,376
R01 · FY2024 · CA · contact PI
HER3-PHF8 signaling axis in triple-negative breast cancer progression$416,723
R01 · FY2023 · CA · contact PI
ErbB3-miRNA axis in tumor metastasis of erbB2-positive breast cancer$336,263
R01 · FY2020 · CA · contact PI
ErbB3-miRNA axis in tumor metastasis of erbB2-positive breast cancer$326,175
R01 · FY2019 · CA · contact PI
ErbB3-miRNA axis in tumor metastasis of erbB2-positive breast cancer$355,539
R01 · FY2018 · CA · contact PI
ErbB3-miRNA axis in tumor metastasis of erbB2-positive breast cancer$350,465
R01 · FY2017 · CA · contact PI
ErbB3-miRNA axis in tumor metastasis of erbB2-positive breast cancer$333,204
R01 · FY2016 · CA · contact PI
Survivin-targeting miRNAs in erbB3 promotion of erbB2-positive breast cancer$77,646
R03 · FY2015 · CA · contact PI
Survivin-targeting miRNAs in erbB3 promotion of erbB2-positive breast cancer$77,396
R03 · FY2014 · CA · contact PI